Stock Report

Download full stock data and analysis for free Last Updated: 10-Oct-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Halozyme Therapeutics (HALO) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$112.34

up-down-arrow $2.50 (2.28%)

As on 09-Oct-2026 13:37EDT

Market cap

info icon

$12,469 Mln

Revenue (TTM)

info icon

$1,664 Mln

P/E Ratio

info icon

31.4

P/B Ratio

info icon

88.9

Div. Yield

info icon

0 %

Edit peer-selector-edit
Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)
 12,469 16,732 14,995 14,468 11,538
Revenue ($ Mln)
 1,664 2,782 1,054 2,436 1,284
Net Profit ($ Mln)
 413.60 491.50 755.85 860.62 -325.10
Net Margin (%)
 24.86 17.67 71.69 35.33 -25.32
RoE (%)
 430.03 110.09 -- 42.98 -57.72
Price to Earnings
 31.39 35.22 17.89 18.36 --
Price-To-Book
 88.91 39.70 8.91 7.82 22.63

Income Statement ($ Mln)

Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Operating Revenue arrow
1,663.74 2,782.29 1,054.37 2,435.92 1,283.94
Cost of Revenue arrow
363.07 1,982.07 103.47 85.67 109.42
Gross Profit arrow
1,091.18 760.62 588.53 2,236.43 902.26
Operating Expenses arrow
356.18 216.81 841.45 1,378.74 1,497.13
Operating Profit (EBIT) arrow
944.49 583.40 109.45 971.51 -322.62
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
583.34 598.92 101.11 1,035.47 -325.10
Provision for Tax arrow
169.74 107.42 -654.74 174.84 0.00
Profit after Tax (Net Income) arrow
413.60 491.50 755.85 860.62 -325.10
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 0.00 0.00 0.00 0.00

Liabilities ($ Mln)

Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Shareholder's Funds arrow
143.54 433.86 1,435.90 1,843.76 523.72
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
2,089.43 187.89 384.48 288.55 346.72
Current Liabilities arrow
344.44 1,435.43 464.70 361.93 374.20
Total Liabilities arrow
2,525.32 1,975.47 1,302.02 2,844.42 1,259.59

Assets ($ Mln)

Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Non-Current Assets arrow
1,644.38 1,006.90 895.24 1,243.41 45.47
Current Assets arrow
933.02 1,050.29 1,389.84 1,250.82 1,199.18
Total Assets arrow
2,525.32 1,975.47 1,302.02 2,844.42 1,259.59
Total Debt* arrow
2,146.65 120.10 449.89 165.93 347.75
Net Current Assets arrow
588.59 -385.14 925.52 888.90 824.98

Cashflow ($ Mln)

Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Cash From Operating Activities arrow
651.56 713.22 51.77 884.27 -189.55
Cash Flow from Investing Activities arrow
-545.81 -31.14 -8.15 350.44 32.32
Cash from Financing Activities arrow
-85.17 -860.39 34.89 -969.59 255.98
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
ROCE (%) arrow
15.61 53.56 -30.01 32.82 -31.49
ROE (%) arrow
430.03 110.09 163.18 42.98 -57.72
ROA (%) arrow
16.19 15.64 31.68 29.32 -22.97
EBIT Margin (%) arrow
36.28 21.13 5.73 41.23 -22.87
Net Margin (%) arrow
24.86 17.67 71.69 35.33 -25.32
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Revenue Growth (%) arrow
41.15 24.67 114.85 9.23 149.04
EBIT Growth (%) arrow
-14.99 18.70 136.39 27.56 -9.48
Net Profit Growth (%) arrow
-25.78 17.50 378.76 42.89 -15.32
EPS Growth (%) arrow
-23.48 26.84 353.27 50.42 -0.64
Book Value Growth (%) arrow
-55.81 164.02 816.12 -0.70 -42.66

Valuation Ratios

 Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Price / Earnings arrow
24.99 36.06 -59.76 15.79 -45.32
Price / Book Value arrow
162.23 35.44 -80.42 5.72 21.68
Dividend Yield (%) arrow
-- -- -- -- --
EV/EBITDA arrow
17.31 28.08 -121.54 12.44 -47.02
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Debt to Equity arrow
13.50 0.00 0.27 0.00 0.65
Short term debt to equity ratio arrow
1.46 0.00 0.05 0.00 0.00
Current Ratio arrow
2.71 0.73 2.99 3.46 3.20
Quick Ratio arrow
2.31 0.73 2.32 3.38 2.94
Interest Coverage arrow
29.73 -- 1.62 -- -9.32

Operating Efficiency Ratios

 Halozyme Therapeutics (HALO) Medpace Holdings (MEDP) Ascendis Pharma A/S - ADR Exelixis (EXEL) Madrigal Pharmaceuticals (MDGL)
Debtors to sales (%) arrow
27.40 15.88 21.25 13.74 14.98
Asset Turnover arrow
0.65 0.89 0.44 0.83 0.91
Receivable days arrow
98.04 50.42 85.52 43.48 35.88
Inventory Days arrow
190.34 -- 1,056.70 96.17 354.23
Payable days arrow
18.62 6.26 331.01 147.97 300.79
Cash Conversion Cycle arrow
269.75 -- 811.21 -8.32 89.33
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...